Chronic Myeloid Leukemia News
Asciminib appeared to have clinical activity in a population of heavily pretreated patients with chronic myeloid leukemia, including those with a T315I mutation.
This study assessed levels of adherence to antihypertensive, lipid-lowering, and antidiabetic therapy in patients initiating oral oncology therapy for a hematologic cancer.
Patients received 50 mg dasatinib daily and demonstrated 2-year rates of overall and event-free survival of 100%.
Mortality risk significantly higher for patients with 20 to 29 percent versus less than 20 percent blasts.
Using validated assessment tools, researchers compared patients’ perceptions of HRQOL while undergoing treatment for CML with 1 of 2 TKIs.
Nilotinib was associated with high adherence to treatment and fairly high quality of life, and nearly all evaluated patients achieved a major molecular response.
An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.
A significantly greater proportion of patients in the flumatinib group had a complete molecular response at 12 months compared with in the imatinib group.
In patients who have been newly diagnosed with AP-CML, the initiation of TKI2 therapies in the frontline setting provided excellent responses and survival rates.
Although the study suggested the efficacy of the branded version was superior to its generic counterpart, more research may be necessary to tease out manufacturer differences.
A prototype intervention increased adherence to tyrosine kinase inhibitor therapy in some patients with chronic myeloid leukemia.
A new method for rapid, ultrasensitive detection of BCR-ABL1 mRNA in chronic myeloid leukemia was described; the tool may have diagnostic utility.
The addition of AR-42 to imatinib yielded synergistic activity in chronic myeloid leukemia cells and also appeared to reverse therapeutic resistance.
Increased costs were found to be a result of more infections.
For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.
Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.
For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.
Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.
Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.